Targeting Infectious Disease - for a Safer World

In Memoriam

The Company is developing drugs for the treatment of Anthrax intoxication following exposure to Anthrax spores and for treatment of botulism in humans caused by BoNT type A intoxication.

Hawaii Biotech’s vaccine platform includes multiple recombinant protein subunits vaccine development candidates produced from our proprietary protein production platform.

Hawaii Biotech produces high quality proteins that engender immune responses equivalent to or better than traditional live or inactivated virus approaches. Our saponin adjuvant, GPI-0100, helps elicit broad immune responses to both vaccines and therapeutics.

Medical Counter Measures

The Company is developing drugs for the treatment of Anthrax intoxication following exposure to Anthrax spores and for treatment of botulism in humans caused by BoNT type A intoxication.

Vaccine Platform

Hawaii Biotech’s vaccine platform includes multiple recombinant protein subunits vaccine development candidates produced from our proprietary protein production platform.

Proteins & Adjuvants

Hawaii Biotech produces high quality proteins that engender immune responses equivalent to or better than traditional live or inactivated virus approaches. Our saponin adjuvant, GPI-0100, helps elicit broad immune responses to both vaccines and therapeutics.